Earnings call transcript: SIGA Technologies Q4 2025 shows mixed market reaction

SIGA reported FY2025 net income of $23M on $95M revenue with $155M cash and zero debt; FY diluted EPS was $0.32 while Q4 EPS was -$0.08. Product revenues totaled ~$88M (oral $53M, IV $26M, international $6M) with pretax operating income of ~$24M and $26M of U.S. government orders outstanding targeting delivery in 2026. Shares fell 2.23% in after-hours trading then recovered 4.53% in premarket, trading near a 52-week low. Key near-term risks are likely EMA withdrawal of the mpox indication and concentration risk from reliance on U.S. government procurement.

Analysis

SIGA presents an option-like equity: outcomes hinge on episodic external decisions rather than organic growth trends, which inflates implied volatility and makes single-event catalysts disproportionately valuable. That lumpy cash-flow profile means market moves will be binary and amplified — a procurement award or favorable regulatory clarity can re-rate the equity sharply, while delays or label reductions can compress multiple and force a prolonged dead-money period.

Regulatory ambiguity in a key market creates a two-sided payoff over the coming 3–12 months: favorable resolution reduces perceived tail risk and unlocks repeat international tenders, while an adverse ruling removes a discrete commercial channel and lowers the probability of near-term foreign orders. Separately, successful pathway progression for adjacent indications (post-exposure or pediatric formulations) would convert episodic procurement into more predictable demand, materially changing the revenue cadence and valuation framework.

From a competitive and supply-chain angle, governments’ desire to diversify medical countermeasure suppliers favors players that can execute complex procurement and domestic-scale manufacturing; that structural preference benefits contractors with established government relationships and raises barriers for pure commercial antivirals. A pivot toward more international, higher-margin buyers would expand gross margins and reduce concentration risk, creating positive second-order effects for FCF conversion and potential capital returns.

Balance-sheet flexibility is the underappreciated buffer: it lowers near-term existential risk and creates optionality for disciplined M&A or shareholder returns if revenue lags. The current risk/reward is skewed — downside is concentrated around timing and regulatory outcomes, while upside is non-linear if several catalysts land within a 6–12 month window.

Key Decisions for Investors

• Long equity + protective put (SIGA): Buy SIGA shares and simultaneously purchase a 3–6 month put ~15–20% OTM to limit downside from a delayed procurement or adverse regulatory step. Target hold 6–12 months; take profits at +80–120% or if a new multi-year government contract is announced. Rationale: protects downside while preserving asymmetric upside to binary procurement/regulatory outcomes.
• Event-driven call spread (SIGA): Buy 12-month call LEAP ~25–35% OTM and sell a nearer-term (6–9 month) call ~60–80% OTM to finance premium. Entry within next 4–8 weeks to capture potential rolling procurement signals and upcoming regulatory windows. Max loss = net premium; reward 3–5x if positive catalysts materialize.
• Relative-value pair (SIGA long / XBI short): Long SIGA equity and short an equivalent beta-weighted position in the small-cap biotech ETF (XBI) to neutralize sector volatility. Timeframe 3–9 months. This isolates company-specific upside from broader biotech moves — expected payoff if company-specific procurement/regulatory catalysts resolve positively.
• Income tilt for conservative holders (SIGA covered call): If already long, sell 3–6 month covered calls ~20% OTM to harvest premium while retaining moderate upside. Use this if timeline for catalysts is uncertain and you prefer yield over volatility capture.